You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

exon skipping

Showing 1 - 25 of 287
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Duchenne Muscular Dystrophy Trial (PGN-EDO51)

Not yet recruiting
  • Duchenne Muscular Dystrophy
  • (no location specified)
Oct 5, 2023

Duchenne Muscular Dystrophy, Exon 44 Trial in San Antonio (AOC 1044, Placebo)

Recruiting
  • Duchenne Muscular Dystrophy
  • Exon 44
  • AOC 1044
  • Placebo
  • San Antonio, Texas
    Worldwide Clinical Trials (Part A only)
Jan 2, 2023

Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain

Completed
  • Metastatic Non-Small Cell Lung Cancer
  • East Hanover, New Jersey
    18 Novartis Investigative Sites in the US
Dec 29, 2022

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

    Recruiting
    • Non-Small Cell Lung Carcinoma
    • Capmatinib 150 mg
    • Capmatinib 200 mg
    • Guwahati, Assam, India
    • +7 more
    Dec 19, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer Trial in San Francisco (Capmatinib, Trametinib)

    Recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • Stage IV Lung Cancer
    • San Francisco, California
      University of California San Francisco
    Aug 15, 2022

    Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

    Not yet recruiting
    • Recurrent Lung Non-Small Cell Carcinoma
    • Stage IV Lung Cancer AJCC v8
    • Biospecimen Collection
    • +5 more
    • (no location specified)
    Sep 7, 2023

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    Advanced NSCLC Trial (CT053PTSA)

    Not yet recruiting
    • Advanced NSCLC
    • (no location specified)
    Jul 29, 2021

    Duchenne Muscular Dystrophy Trial in Worldwide (Eteplirsen)

    Completed
    Has Results
    • Duchenne Muscular Dystrophy
    • Gent, Belgium
    • +3 more
    Nov 10, 2021

    NSCLC (NSCLC) Trial in China (Capmatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Xiamen, Fujian, China
    • +18 more
    Jan 27, 2023

    Carcinoma, Non-Small Cell Lung, NSCLC, Non-Small-Cell Lung Carcinoma Trial (Capmatinib)

    Available
    • Carcinoma, Non-Small Cell Lung
    • +3 more
    • (no location specified)
    Aug 31, 2021

    NSCLC Trial in United States (capmatinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • La Jolla, California
    • +7 more
    Oct 5, 2022

    Duchenne Muscular Dystrophy Trial in Los Angeles, Chicago, Baltimore (SRP-4045, Placebo)

    Completed
    Has Results
    • Duchenne Muscular Dystrophy
    • Los Angeles, California
    • +2 more
    Apr 23, 2021

    Muscular Dystrophy, Duchenne, DMD Trial (viltolarsen)

    Approved for marketing
    • Muscular Dystrophy, Duchenne
    • DMD
    • (no location specified)
    Aug 14, 2020

    Duchenne Muscular Dystrophy Trial in Worldwide (SRP-4045, SRP-4053, Placebo)

    Active, not recruiting
    • Duchenne Muscular Dystrophy
    • Phoenix, Arizona
    • +74 more
    Jan 17, 2023

    Duchenne Muscular Dystrophy Trial in Worldwide (Placebo, SRP-4053)

    Completed
    Has Results
    • Duchenne Muscular Dystrophy
    • Boston, Massachusetts
    • +4 more
    Oct 14, 2020

    Duchenne Muscular Dystrophy Trial in Worldwide (Viltolarsen, Placebo)

    Recruiting
    • Duchenne Muscular Dystrophy
    • Sacramento, California
    • +38 more
    May 23, 2022

    Solid Tumor, MET Exon 14 Skipping Mutation, MET Amplification Trial in Korea, Republic of (Tepotinib)

    Recruiting
    • Solid Tumor
    • +2 more
    • Hwasun, Chonnam, Korea, Republic of
    • +21 more
    Nov 30, 2020

    Duchenne Muscular Dystrophy Trial in Columbus (Casimersen, Eteplirsen, Golodirsen)

    Active, not recruiting
    • Duchenne Muscular Dystrophy
    • Columbus, Ohio
      Nationwide Children's Hospital
    Oct 11, 2021

    Special Drug Use-results Surveillance of Tabrecta Tablets

    Recruiting
    • Non-small Cell Lung Cancer
    • Tabrecta tablets
    • Nagoya, Aichi, Japan
    • +44 more
    Aug 1, 2022

    Malignant Non-small Cell Tumor of Lung Stage IV Trial in Boston (Capmatinib (INC280))

    Completed
    Has Results
    • Malignant Non-small Cell Neoplasm of Lung Stage IV
    • Capmatinib (INC280)
    • Boston, Massachusetts
      Massachusetts General Hospital
    Mar 11, 2022

    Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Canada, France, United States (QR-421a, Sham-procedure (dose

    Completed
    • Retinitis Pigmentosa
    • +7 more
    • QR-421a
    • Sham-procedure (dose cohort 1&2 only)
    • Boston, Massachusetts
    • +6 more
    Apr 19, 2022

    Duchenne Muscular Dystrophy Trial in Garches (Phase 1, SQY51, Phase 2a, SQY51 (cohort 1), Phase 2a, SQY51 (cohort 2))

    Recruiting
    • Duchenne Muscular Dystrophy
    • Phase 1, SQY51
    • +3 more
    • Garches, France
      Hôpital Raymond Poincaré
    Mar 7, 2023

    Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Worldwide (Ultevursen, Sham-procedure)

    Recruiting
    • Retinitis Pigmentosa
    • +7 more
    • San Diego, California
    • +14 more
    Jul 29, 2022